For over 30 years our companies have made treating complex and life-threatening conditions possible, supporting clinicians, healthcare systems and governments while offering hope to patients and their families.

  • July 2023

    Acquired Vistogard and Xuriden

  • April 2022

    Acquired the rights to Xermelo outside the US and Japan from Ipsen.

  • January 2022

    Voraxaze approved in Europe.

  • March 2021

    SERB acquires BTG Specialty Pharmaceuticals, adding a US commercial presence, bio-manufacturing and R&D capabilities, and products including DIGIFab, Voraxaze, and CroFab. 

  • 2020

    Licensed Ammonul from Bausch & Lomb.

  • 2020

    Acquired Effortil from Sanofi SA.

  • March 2020

    SERB acquires Veriton Pharma, adding a direct commercial presence in the UK, the Middle East and Australia, and adding rare disease products such as Epistatus.

  • 2019

    BTG plc acquired by Boston Scientific – BTG Specialty Pharmaceutical re-organises as a self-sufficient business. 

  • 2019

    Licensed Firdapse from Biomarin (Europe).

  • 2018

    SERB acquires critical care business of EUSA Pharma, including EUSA’s field-based critical care sales teams and products including Fomepizole, Collatamp, Custodiol (critical care), Xenazine.

  • 2018

    Thyrosafe/Kaliumjodid acquired from Recipharm.

  • 2017

    Toxogonin acquired from Merck.

  • October 2017

    Special Products Limited changed its company name to Veriton Pharma.

  • September 2017

    Epistatus is licensed in the UK

  • 2017

    Charterhouse Capital Partners, a London-based private equity firm, acquires a majority stake in SERB and dedicates significant financial and human resources to the company’s development.

  • 2015

    Cyanokit® acquired from Merck.

  • 2013

    Licensed Radiogardase from Heyl Pharmaceuticals.

  • 2012

    Voraxaze® (glucarpidase) approved and launched in the US.

  • 2010

    DIGIFab® (digoxin immune Fab (ovine)) receives first European regulatory approval

  • 2010

    BTG begins directly selling its own products in the US.

  • 2008

    BTG Plc acquired Protherics plc, a developer of new immunotherapeutic products and therapies.

  • 2002

    DIGIFab® (digoxin immune Fab (ovine)) launched in the US.

  • 2001

    CroFab® (crotalidae polyvalent immune fab (ovine)) launched in the US.

  • 1997

    Special Products Ltd (later Veriton Pharma) founded by Dr Graham March, a pharmacist with experience working at Great Ormond Street Hospital, and at major pharmaceutical companies. The company focused on unlicensed medicines for patients with special requirements.

  • 1981

    BTG (British Technology Group) is formed by the British government from the merger of the National Research & Development Council and the National Enterprise Board. The group is later privatised (1992) and listed on the London Stock exchange (1995).

  • 1951

    SERB (Société d’Études et de Recherches Biologiques) is created in Paris. 

You are leaving the SERB.com global corporate website
This link will take you to a third-party website, the terms of use and the privacy policy of which may be different. SERB declines all responsibility in that regard and in case of a breach of its privacy policy by the third-party website. Moreover, SERB is not responsible for any information or opinion contained in any third-party website.
Choose your region